Presenilin immunoreactivity in Alzheimer's disease

European Journal of Neurology

Volumn 12, Issue 9, 2005, Pages 700-706

  Panegyres, P K ^a   Toufexis, K ^a  

^a Mount Medical Centre   (Australia)

Author keywords

secretase; Alzheimer's disease; Dementia; Presenilin 1 and 2

Indexed keywords

GAMMA SECRETASE; POLYCLONAL ANTIBODY; PRESENILIN 1; PRESENILIN 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOTTING, WESTERN; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEURONS; PRESENILIN-1; PRESENILIN-2; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 24744459424     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01050.x     Document Type: Article

References (41)

1. Bagshaw RD, Pasternak SH, Mahuran DJ, Callahan JW (2003). Nicastrin is a resident lysosomal membrane protein. Biochem Biophys Res Comm 300:615-618.
2. Borchelt DR, Thinakaran G, Eckman CB et al. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17:105-113.
3. Checler F (2001). The multiple paradoxes of presenilins. J Neurochem 76:1621-1627.
4. Chen F, Yu G, Arawaka S et al. (2001). Nicastrin binds to membrane-tethered Notch. Nature Cell Biol 3:751-754.
5. Chung HM, Struhl G (2001). Nicastrin is required for presenilin-mediated transmembrane cleavage in Drosophila. Nature Cell Biol 3:1129-1132.
6. Citron M, Westaway D, Xia W et al. (1997). Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67-72.
7. De Strooper B, Saftig P, Craessaerts K et al. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390.
8. De Strooper B, Annaeret W, Cupers P et al. (1999). A presenilin-1- dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518-522.
9. Diehlmann A, Ida N, Weggen S et al. (1999). Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. J Neurosci Res 56:405-419.
10. Esler WP, Kimberly WT, Ostaszewski BL et al. (2002). Activity-dependent isolation of the presenilin- gamma-secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci USA 99:2720-2725.
11. Fabian VA, Jones TM, Wilton SD et al. (1996). Alzheimer's disease and apolipoprotein E genotype in Western Australia: an autopsy-verified series. Med J Aust 165:77-80.
12. Giannakopoulos P, Bouras C, Kovari E et al. (1997). Presenilin-1 immunoreactive neurons are preserved in late onset Alzheimer's disease. Am J Pathol 150:429-436.
13. Glenner GG, Wong CW (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 120:885-890.
14. Golde TE, Younkin SG (2001). Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol Med 7:264-269.
15. Goutte C, Hepler W, Mickey KM, Priess JR (2000). APH-2 encodes a novel extracellular protein required for GLP-1-mediated signaling. Development 127:2481-2492.
16. Hendriks L, De Jonghe C, Ursula Lübke Woodrow S et al. (1998). Immunoreactivity of presenilin-1 and tau in Alzheimer's disease brain. Exp Neurol 149:341-348.
17. Hu Y, Ye Y, Fortini ME (2002). Nicastrin is required for gamma-secretase cleavage of the Drosophila Notch receptor. Develop Cell 2:69-78.
18. Huynh DP, Vinters HV, Ho DHD, Ho VV, Pulst S-M (1997). Neuronal expression and intracellular localization of presenilins in normal and Alzheimer disease brains. J Neuropathol Exp Neurol 56:1009-1017.
19. Janssen JC, Lantos PL, Fox NC et al. (2001). Autopsy-confirmed familial early-onset Alzheimer disease caused by the L153V presenilin 1 mutation. Arch Neurol 58:963-968.
20. Kim KS, Wegiel J, Sapienza V, Chen J, Hong H, Wisniewski HM (1997). Immunoreactivity of presenilin-1 in human, rat and mouse brain. Brain Res 757:159-163.
21. Lemere CA, Lopera F, Kosik KS et al. (1996). The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2:1146-1150.
22. Levey AI, Heilman CJ, Lah JJ et al. (1997). Presenilin-1 protein expression in familial and sporadic Alzheimer's disease. Ann Neurol 41:742-753.
23. Levitan D, Greenwald I (1995). Facilitation of lin-12-mediated signalling by se1-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377:351-354.
24. Li YM, Lai MT, Xu M et al. (2000a). Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-694.
25. Li YM, Lai MT, Xu M et al. (2000b). Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 97:6138-6143.
26. Lopez-Schier H, St Johnson D (2002). Drosophila nicastrin is essential for the intramembranous cleavage of notch. Develop Cell 2:79-89.
27. Mann DM, Iwatsubo T, Cairns NJ et al. (1996). Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann Neurol 40:149-156.
28. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
30. Panegyres PK (2001). The functions of the amyloid precursor protein gene. Rev Neurosci 12:1-39.
31. Panegyres PK, Goldblatt J, Walpole I, Connor C, Liebeck T, Harrop K (2000). Genetic testing for Alzheimer's disease. Med J Aust 172:339-343.
32. Petit A, Bihel F, da Costa CA, Pourquie O, Checler F, Kraus J-L (2001). New Protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nature Cell Biol 3:507-511.
33. Scheuner D, Eckman C, Jensen M et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870.
34. Selkoe DJ (2001). Alzheimer's disease: genes, proteins and therapy. Physiol Rev 81:741-766.
35. Small DH (2001). The role of presenilins in γ-secretase activity: catalyst or cofactor? J Neurochem 76:1612-1614.
36. Uchihara T, el Hachini HK, Duyckaerts C et al. (1996). Widespread immunoreactivity of presenilin in neurons of normal and Alzheimer's disease brains: Double-Caboling immunohistochemical study. Acta Neuropathol (Berl) 92:325-330.
37. Weber LL, Leissring MA, Yang AJ, Glabe CG, Cribbs DH, LaFeria FM (1997). Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Exp Neurol 143:37-44.
38. Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer TA (1998). Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain. Clin Neurosci 9:3279-3283.
39. Wisniewski T, Dowjat WK, Permanne B et al. (1997). Presenilin-1 is associated with Alzheimer's disease amyloid. Am J Pathol 151:601-610.
40. Wolfe MS, Haass C (2001). The role of presenilins in γ-secretase activity. J Biol Chem 276:5413-5416.
41. Yu G, Nishimura M, Arakawa S et al. (2000). Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407:48-54.